Sanofi's Dengvaxia launch rocked by turmoil in Latin America

An article by FiercePharma
July 29, 2016

Having spent two decades and $1.5 billion developing its first-of-a-kind dengue vaccine, Sanofi is sure to be unhappy to report that Dengvaxia’s launch has been slower than anticipated.

In second quarter results issued Friday, the French drugmaker said it’s likely going to miss its Dengvaxia sales estimates for the year of €200 million. The vaccine turned in €20 million in first half sales and just €1 million in the second quarter.

The high-stakes rollout has seen delays in Latin America due to political and economic turmoil, Sanofi said in its earnings statement. So far, the Philippines is the only country to have signed on for a vaccination campaign utilizing the vaccine, though Brazil’s Paraná State recently announced an initiative that’ll cover 500,000 residents, Sanofi said.

The vaccine has garnered 5 approvals with others pending throughout Asia. But in Brazil, the Butantan Institute recently initiated a Phase III trial in 17,000 people with another dengue vaccine candidate created by NIH scientists. Takeda is also working on a shot that could steal market share by 2020, analysts have predicted.


Read the rest here